Astagraf XL to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation

Trial Profile

Astagraf XL to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Acronyms ASTOUND
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 12 May 2017 Planned End Date changed from 1 Oct 2019 to 31 Mar 2020.
    • 12 May 2017 Planned primary completion date changed from 1 Oct 2019 to 31 Mar 2020.
    • 27 Oct 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top